NDAORALTABLETPriority Review
Approved
Jun 1950
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Priority Review
TAPAZOLE (methimazole) by Pfizer is thyroid hormone synthesis inhibitors [moa]. First approved in 1950.
Drug data last refreshed 3d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TAPAZOLE (methimazole) is an oral small-molecule thyroid hormone synthesis inhibitor approved in 1950 for treating Graves' disease, an autoimmune condition causing hyperthyroidism. It works by blocking the enzyme responsible for incorporating iodine into thyroid hormones, reducing their production and alleviating thyroid overactivity symptoms.
LOE Approaching
As an established generic-vulnerable product with approaching loss of exclusivity, brand team size is likely minimal with focus shifting toward lifecycle management rather than growth initiatives.
Mechanism of Action
Thyroid Hormone Synthesis Inhibitors
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on TAPAZOLE offers limited career growth opportunity given its LOE-approaching status and minimal linked job openings (0 identified). Roles on this asset are typically focused on defending market share, managing generic transition, and optimizing profitability rather than building new commercial infrastructure.
Regulatory Affairs SpecialistMarket Access Manager
Worked on TAPAZOLE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.